Skip to content

EBIT at other companies

Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$53.42M-148%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$92.5M-47.1%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$24.22M+10.7%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
-$3.4M+99.3%
Precigen logo
PrecigenPGEN
-$5.99M+73.5%
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.65B+319%
Enterprise value$1.6B+1,325%
P/S22.8×-379×

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Calculated from Septerna, Inc.’s reported figures.

Plus components not separately reported this period.

The official record: Septerna, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s EBIT?
Septerna, Inc. (SEPN) reported EBIT of -$13.3M in Q1 2026.
How has Septerna, Inc.'s EBIT changed year-over-year?
Septerna, Inc.'s EBIT increased by 48.7% year-over-year, from -$25.91M to -$13.3M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.